Haleon, University of Sydney partner for osteoarthritis research

Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility.

The fellowship will fund a postdoctoral researcher to work under the guidance of world-leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.

Hunter said the research collaboration represents a shared focus and investment in improving osteoarthritis management. “This is a disabling disease that has a huge impact on the people affected.

“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year project of this nature that has osteoarthritis as its focus,” Hunter said.

Haleon, the maker of consumer health products like Panadol, Voltaren, Centrum and Caltrate, and the University of Sydney are coming together with the shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.

Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, said the fellowship is consistent with Haleon’s commitment to science and innovation in consumer health care.

“As global leaders in pain management and everyday health, Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes. This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” Thampi said.

Image credit: iStock.com/designer491